does semaglutide cause heart attack The Cardioprotective Effects of Exceed Those of Dietary Weight Loss in Mice With HFpEF Semaglutide Demonstrates Impressive Heart Benefits

These results come from different trials in different populations, so they arent a direct comparison, but they do suggest that switching from an injectable GLP-1 to a tablet may mean slower progress or less total weight loss for some people

"There's a lot of other things they do

High-Protein Foods (Keeps You Full & Supports Muscle) Include lean proteins to maintain muscle mass and promote satiety: Chicken, turkey, beef, pork, veal, steak Seafood: Salmon, tuna, sardines, shrimp, mackerel Whole eggs, Greek yogurt, cottage cheese High-Fiber Foods (Supports Digestion & Reduces Cravings) Fiber-rich foods improve gut health and help you feel full longer: Leafy greens, broccoli, zucchini, cauliflower, Brussels sprouts, spinach Low-sugar fruits: Berries, apples, pears Legumes: Lentils, black beans, chickpeas Healthy Fats (Curbs Hunger & Supports Heart Health) Adding healthy fats can help regulate appetite and promote overall well-being: Avocados, nuts & seeds (almonds, chia, flax, pumpkin) Olive oil, coconut oil, butter (in moderation) Fatty fish: Salmon, sardines, mackerel, tuna Hydrating & Gut-Friendly Foods (Improves Digestion & Hydration) Staying hydrated and supporting gut health can help prevent common side effects: Water, herbal teas Bone broth (gentle on digestion, nutrient-rich) Fermented foods: Kimchi, sauerkraut, Greek yogurt Following a GLP-1 meal plan can enhance your weight loss results while minimizing side effects like nausea and bloating

Can eating carbohydrates on Ozempic cause low blood sugar

In cardiovascular outcome trials (CVOTs) such as Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA-REG OUTCOME), CANagliflozin cardioVascular Assessment Study (CANVAS) and The Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) [6], they reduced the onset and progression of DKD, which was confirmed in the dedicated kidney trial The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), which showed a canagliflozin-induced risk reduction for ESKD in people with DKD by 32% [7]

Sikirica, M